NeuroSense Therapeutics Ltd.
NRSN
$1.14
-$0.0301-2.57%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -7.17% | 75.64% | 16.96% | 13.70% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -22.57% | -12.93% | 11.40% | 10.09% | |
| Operating Income | 22.57% | 12.93% | -11.40% | -10.09% | |
| Income Before Tax | -174.74% | -1.35% | 68.03% | 41.22% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -174.74% | -1.35% | 68.03% | 41.22% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -174.74% | -1.35% | 68.03% | 41.22% | |
| EBIT | 22.57% | 12.93% | -11.40% | -10.09% | |
| EBITDA | 22.57% | 12.98% | -11.38% | -10.03% | |
| EPS Basic | -96.40% | 19.61% | 78.96% | 50.10% | |
| Normalized Basic EPS | -96.27% | 19.63% | 78.96% | -- | |
| EPS Diluted | -96.40% | 19.61% | 78.96% | 50.10% | |
| Normalized Diluted EPS | -96.27% | 19.63% | 78.96% | -- | |
| Average Basic Shares Outstanding | 40.02% | 26.12% | 51.78% | 17.79% | |
| Average Diluted Shares Outstanding | 40.02% | 26.12% | 51.78% | 17.79% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |